Pharmaxis Limited is a biotechnology company focused on the discovery, development and commercialization of innovative small-molecule therapies for respiratory, fibrotic and inflammatory diseases. Founded in 1998 and headquartered in Sydney, Australia, the company is publicly traded on the Australian Securities Exchange under the ticker PXS and on the OTC Markets as PXSLY. Pharmaxis combines in-house chemistry expertise with preclinical and clinical development capabilities to advance its pipeline candidates toward regulatory approval.
The company’s marketed products address unmet needs in airway disease diagnostics and treatment. Aridol, a bronchial challenge test for asthma diagnosis, has been approved in Europe, Australia and other regions, and is used by pulmonologists to assess airway hyperresponsiveness. Bronchitol, a sugar-based inhaled therapy for cystic fibrosis, has received marketing authorization in Europe and other territories, with commercial partnerships established to support its distribution and physician uptake. In parallel, Pharmaxis is advancing development candidates targeting fibrotic disorders, including inhibitors of key lysyl oxidase enzymes implicated in tissue scarring.
Pharmaxis’ research and development operations are based in Sydney, where multidisciplinary teams work on medicinal chemistry, pharmacology and formulation to optimize drug candidates. The company collaborates with global pharmaceutical partners for late-stage clinical trials and commercialization, leveraging established distribution channels in North America, Europe and Asia. Led by an experienced management team with backgrounds in biotech innovation and regulatory affairs, Pharmaxis continues to build its pipeline while supporting its existing commercial products in markets worldwide.
AI Generated. May Contain Errors.
Free PXSLY Stock Alerts